MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MeiraGTx Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.45+0.17 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
82.5%
79M of 96M shares
Institutional holders
157
39 new, 12 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
0 buys · 8 sales
Net sold $3.83M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Rosen | 9,100,000 | 9.83% | 13G (passive) amendment | Jun 30, 2026 |
| VOLUNTARY) Johnson & Johnson Innovation-JJDC, Inc. | 6,641,064 | 8.60% | 13G (passive) amendment | Sep 30, 2024 |
| Rubric Capital Management LP | 6,175,331 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Adage Capital Partners, L.P. | 5,291,618 | 8.32% | 13G (passive) amendment | Dec 31, 2023 |
| Phillip Gross | 4,184,578 | 5.20% | 13G (passive) amendment | Sep 30, 2025 |
| Adena Estate Inc. | 3,266,806 | 5.10% | 13G (passive) | Dec 31, 2023 |
| Sanofi | 12,197,737 | 15.80% | 13G (passive) amendment | Aug 12, 2024 |
| Perceptive Advisors LLC | 11,742,117 | 12.60% | 13D (active) amendment | Apr 17, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 10,441,562 | 12.90% | 13D (active) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MGTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sanofi | 12,197,737 | 12.70% | $164.79M | – | 30.86% |
| Perceptive Advisors LLC | 10,786,658 | 11.23% | $145.73M | +460,555 | 2.19% |
| Rubric Capital Management LP | 9,100,000 | 9.47% | $122.94M | +2,100,000 | 1.13% |
| Johnson & Johnson | 6,641,064 | 6.91% | $89.72M | – | 11.23% |
| BlackRock, Inc. | 4,757,178 | 4.95% | $64.27M | +1,589,030 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 4,400,000 | 4.58% | $59.44M | +400,000 | 0.08% |
| Opaleye Management Inc. | 3,550,000 | 3.70% | $47.96M | +1,426,741 | 4.34% |
| Millennium Management LLC | 2,971,752 | 3.09% | $40.15M | −493,947 | 0.01% |
| 683 Capital Management, LLC | 2,300,000 | 2.39% | $31.07M | −150,000 | 1.53% |
| Woodline Partners LP | 1,500,135 | 1.56% | $20.27M | +1,199,812 | 0.06% |
| State Street Corp | 1,393,222 | 1.45% | $18.82M | +639,844 | 0.00% |
| Morgan Stanley | 1,312,703 | 1.37% | $17.73M | −277,237 | 0.00% |
| Knoll Capital Management, LLC | 1,250,000 | 1.30% | $16.89M | – | 9.42% |
| Kennedy Capital Management LLC | 1,105,421 | 1.15% | $14.93M | +247,042 | 0.26% |
| Long Focus Capital Management, LLC | 1,080,300 | 1.12% | $14.59M | +555,555 | 0.37% |
| Jacobs Levy Equity Management, Inc | 1,015,106 | 1.06% | $13.71M | +1,001,433 | 0.05% |
| D. E. Shaw & Co., Inc. | 852,902 | 0.89% | $11.52M | +427,621 | 0.01% |
| Heights Capital Management, Inc | 850,000 | 0.89% | $11.48M | New | 2.65% |
| Geode Capital Management, LLC | 849,082 | 0.88% | $11.47M | +264,183 | 0.00% |
| Vanguard Portfolio Management LLC | 723,563 | 0.75% | $9.78M | +326,282 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 157 | 79M | 82.5% | 39 / 81 | 22 / 12 | 17M | 5M |
| Q1 2026 | 133 | 67M | 70.2% | 20 / 48 | 40 / 15 | 6M | 3M |
| Q4 2025 | 130 | 65M | 67.9% | 20 / 44 | 34 / 12 | 7M | 6M |
| Q3 2025 | 123 | 64M | 66.8% | 24 / 29 | 39 / 13 | 4M | 4M |
| Q2 2025 | 112 | 65M | 67.2% | 17 / 36 | 39 / 22 | 8M | 3M |
| Q1 2025 | 118 | 60M | 62.5% | 22 / 44 | 33 / 5 | 5M | 3M |
| Q4 2024 | 102 | 58M | 60.5% | 17 / 45 | 22 / 14 | 15M | 3M |
| Q3 2024 | 99 | 46M | 47.4% | 11 / 37 | 30 / 6 | 8M | 1M |
| Q2 2024 | 95 | 41M | 42.5% | 13 / 38 | 29 / 14 | 2M | 1M |
| Q1 2024 | 96 | 40M | 41.5% | 19 / 29 | 30 / 8 | 1M | 1M |
| Q4 2023 | 86 | 40M | 41.3% | 17 / 31 | 24 / 5 | 3M | 1M |
| Q3 2023 | 75 | 38M | 39.3% | 7 / 20 | 23 / 11 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MGTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Nuveen Quant Small Cap Equity Fund | 526,570 | 0.55% | $6.21M | 0.15% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 232,099 | 0.24% | $2.47M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 133,062 | 0.14% | $1.42M | 0.01% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 113,461 | 0.12% | $1.53M | 0.05% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 79,737 | 0.08% | $940.10K | 0.02% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 77,592 | 0.08% | $914.81K | 0.00% | Jul 31, 2026 |
| Nuveen Quant Mid Cap Growth Fund | 71,980 | 0.07% | $848.64K | 0.13% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 57,010 | 0.06% | $672.15K | 0.02% | Jul 31, 2026 |
| AlphaCentric Life Sciences and Healthcare Fund | 54,469 | 0.06% | $735.88K | 1.58% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 52,420 | 0.05% | $708.19K | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 31,787 | 0.03% | $338.53K | 0.02% | May 31, 2026 |
| Small Cap Index Fund | 30,333 | 0.03% | $409.80K | 0.02% | Jun 30, 2026 |
| Small Company Growth Portfolio | 29,450 | 0.03% | $397.87K | 0.02% | Jun 30, 2026 |
| Global X Russell 2000 ETF | 28,718 | 0.03% | $338.59K | 0.02% | Jul 31, 2026 |
| Small Cap Equity Fund | 24,200 | 0.03% | $326.94K | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alexandria Forbes | PRESIDENT & CEO, Director | 1,354,680 | 1.41% | Aug 18, 2026 |
| Richard Giroux | CFO & COO | 998,682 | 1.04% | Jul 21, 2026 |
| Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | 665,958 | 0.69% | Jul 7, 2026 |
| Robert K. Zeldin | CHIEF MEDICAL OFFICER | 146,204 | 0.15% | Jun 29, 2026 |
| Robert J. Wollin | GENERAL COUNSEL AND SECRETARY | 63,326 | 0.07% | Jun 29, 2026 |
| Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | – | – | May 14, 2026 |
| Alan Sebulsky | Director | 34,500 | 0.04% | Sep 24, 2026 |
| Nicole Seligman | Director | 5,000 | 0.01% | Jun 15, 2026 |
| Debra Yu | Director | – | – | Jun 15, 2026 |
| Ellen Hukkelhoven | Director | 0 | – | Jun 15, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director, 10% owner | 10,786,658 | 11.23% | Jun 15, 2026 |
| Joseph Edelman | Director, 10% owner | 12,531,103 | 13.05% | Jun 15, 2026 |
| Thomas E. Shenk | Director | 157,476 | 0.16% | Jun 15, 2026 |
| Advisors Llc Perceptive | Director, 10% owner | 6,933,277 | 7.22% | Jun 15, 2026 |
| Keith R. Harris | Director | 200,000 | 0.21% | Jun 15, 2026 |
| Neil Mendoza | Director | 12,883 | 0.01% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexandria Forbes PRESIDENT & CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −62,000 | $13.86 | $859.32K | 1,325,695 |
| Richard Giroux CFO & COO | Jul 21, 2026 | Sale(10b5-1 plan) | −56,000 | $12.51 | $700.56K | 908,530 |
| Stuart Naylor CHIEF SCI OFCR, OPHTHALMOLOGY | Jul 7, 2026 | Sale(10b5-1 plan) | −2,547 | $13.86 | $35.30K | 665,958 |
| Stuart Naylor CHIEF SCI OFCR, OPHTHALMOLOGY | Jul 7, 2026 | Sale(10b5-1 plan) | −25,112 | $14.90 | $374.17K | 640,846 |
| Keith R. Harris Director | Jun 10, 2026 | Option exercise | +75,000 | – | – | 200,000 |
| Richard Giroux CFO & COO | May 27, 2026 | Gift | −7,000 | – | – | 964,530 |
| Alexandria Forbes PRESIDENT & CEO, Director | May 19, 2026 | Sale(10b5-1 plan) | −62,000 | $9.17 | $568.54K | 1,387,695 |
| Richard Giroux CFO & COO | Apr 21, 2026 | Sale(10b5-1 plan) | −56,000 | $10.22 | $572.32K | 971,530 |
| Life Sciences Master Fund Ltd Perceptive Director, 10% owner | Apr 17, 2026 | Award | +555,555 | $9.00 | $5.00M | 10,786,658 |
| Stuart Naylor CHIEF DEV. OFFICER | Apr 7, 2026 | Sale(10b5-1 plan) | −27,661 | $9.36 | $258.91K | 668,505 |
| Alexandria Forbes PRESIDENT & CEO, Director | Mar 24, 2026 | Sale(10b5-1 plan) | −62,000 | $7.41 | $459.42K | 1,449,695 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2026 | Tax withholding | −2,952 | $7.45 | $21.99K | 172,888 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2026 | Option exercise | +7,500 | – | – | 175,840 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2026 | Option exercise | +11,250 | – | – | 63,326 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2026 | Tax withholding | −5,949 | $7.45 | $44.32K | 57,377 |
| Richard Giroux CFO & COO | Feb 21, 2026 | Option exercise | +60,000 | – | – | 1,059,256 |
| Richard Giroux CFO & COO | Feb 21, 2026 | Tax withholding | −31,726 | $7.45 | $236.36K | 1,027,530 |
| Stuart Naylor CHIEF DEV. OFFICER | Feb 21, 2026 | Option exercise | +25,000 | – | – | 707,916 |
| Stuart Naylor CHIEF DEV. OFFICER | Feb 21, 2026 | Tax withholding | −11,750 | $7.45 | $87.54K | 696,166 |
| Alexandria Forbes PRESIDENT & CEO, Director | Feb 21, 2026 | Option exercise | +62,500 | – | – | 1,544,743 |
| Alexandria Forbes PRESIDENT & CEO, Director | Feb 21, 2026 | Tax withholding | −33,048 | $7.45 | $246.21K | 1,511,695 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 17, 2026 | Tax withholding | −27,206 | $7.42 | $201.87K | 52,076 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 17, 2026 | Option exercise | +50,000 | – | – | 79,282 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 17, 2026 | Tax withholding | −35,250 | $7.42 | $261.56K | 682,916 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 17, 2026 | Option exercise | +75,000 | – | – | 718,166 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 17, 2026 | Tax withholding | −13,951 | $7.42 | $103.52K | 168,340 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 17, 2026 | Option exercise | +35,000 | – | – | 182,291 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 17, 2026 | Tax withholding | −163,916 | $7.42 | $1.22M | 1,482,243 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 17, 2026 | Option exercise | +310,000 | – | – | 1,646,159 |
| Richard Giroux CFO & COO | Jan 17, 2026 | Tax withholding | −163,916 | $7.42 | $1.22M | 999,256 |
| Richard Giroux CFO & COO | Jan 17, 2026 | Option exercise | +310,000 | – | – | 1,163,172 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 7, 2026 | Tax withholding | −7,814 | $7.73 | $60.40K | 146,204 |
| Richard Giroux CFO & COO | Jan 7, 2026 | Option exercise | +52,500 | – | – | 881,994 |
| Richard Giroux CFO & COO | Jan 7, 2026 | Tax withholding | −28,822 | $7.73 | $222.79K | 853,172 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 7, 2026 | Option exercise | +7,500 | – | – | 33,646 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 7, 2026 | Tax withholding | −4,364 | $7.73 | $33.73K | 29,282 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 7, 2026 | Option exercise | +37,500 | – | – | 660,791 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 7, 2026 | Tax withholding | −17,625 | $7.73 | $136.24K | 643,166 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 7, 2026 | Tax withholding | −34,074 | $7.73 | $263.39K | 1,336,159 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 7, 2026 | Option exercise | +62,500 | – | – | 1,370,233 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 7, 2026 | Option exercise | +17,500 | – | – | 154,020 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 7, 2026 | Tax withholding | −6,729 | $7.73 | $52.02K | 147,291 |
| Life Sciences Master Fund Ltd Perceptive Director, 10% owner | Dec 31, 2025 | Returned to company | −2,300,000 | $7.91 | $18.19M | 10,231,103 |
| Alexandria Forbes PRESIDENT & CEO, Director | Dec 23, 2025 | Gift | −6,250 | – | – | 1,307,733 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Nov 20, 2025 | Gift | −5,000 | – | – | 26,146 |
| Richard Giroux CFO & COO | Oct 21, 2025 | Sale(10b5-1 plan) | −24,000 | $8.87 | $212.88K | 829,494 |
| Alexandria Forbes PRESIDENT & CEO, Director | Oct 7, 2025 | Sale(10b5-1 plan) | −47,500 | $8.39 | $398.53K | 1,313,983 |
| Richard Giroux CFO & COO | Jul 22, 2025 | Sale(10b5-1 plan) | −24,000 | $8.52 | $204.48K | 853,494 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jul 8, 2025 | Sale(10b5-1 plan) | −47,500 | $7.97 | $378.58K | 1,361,483 |
| Richard Giroux CFO & COO | Jun 30, 2025 | Gift | −5,000 | – | – | 877,494 |
| Keith R. Harris Director | Jun 6, 2025 | Option exercise | +75,000 | – | – | 125,000 |
| Richard Giroux CFO & COO | Apr 22, 2025 | Sale(10b5-1 plan) | −24,000 | $6.00 | $144.00K | 882,494 |
| Alexandria Forbes PRESIDENT & CEO, Director | Apr 8, 2025 | Sale(10b5-1 plan) | −47,500 | $5.34 | $253.65K | 1,408,983 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2025 | Tax withholding | −12,116 | $7.30 | $88.45K | 31,146 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2025 | Option exercise | +22,500 | – | – | 43,262 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2025 | Tax withholding | −5,903 | $7.30 | $43.09K | 136,520 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2025 | Option exercise | +15,000 | – | – | 142,423 |
| Stuart Naylor CHIEF DEV. OFFICER | Feb 21, 2025 | Option exercise | +50,000 | – | – | 646,791 |
| Stuart Naylor CHIEF DEV. OFFICER | Feb 21, 2025 | Tax withholding | −23,500 | $7.30 | $171.55K | 623,291 |
| Alexandria Forbes PRESIDENT & CEO, Director | Feb 21, 2025 | Tax withholding | −66,095 | $7.30 | $482.49K | 1,456,483 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stuart Naylor Officer | Oct 6, 2026 | 27,659 | $294.32K | Oct 6, 2026 | Restricted Stock Vesting |
| Forbes Alexandria Officer, Director | Aug 18, 2026 | 62,000 | $859.32K | Aug 18, 2026 | Incentive Compensation Stock Grant |
| Giroux Richard Officer | Jul 21, 2026 | 56,000 | $700.56K | Jul 21, 2026 | Incentive Compensation Stock Grant |
| Stuart Naylor Officer | Jul 7, 2026 | 27,659 | $368.69K | Jul 7, 2026 | Restricted Stock Vesting |
| Forbes Alexandria Officer, Director | May 19, 2026 | 62,000 | $568.54K | May 19, 2026 | Incentive Compensation Stock Grant |
| Giroux Richard Officer | Apr 21, 2026 | 56,000 | $572.55K | Apr 21, 2026 | Incentive Compensation Stock Grant |
| Stuart Naylor Officer | Apr 7, 2026 | 27,661 | $258.87K | Apr 7, 2026 | Restricted Stock Vesting |
| Forbes Alexandria Officer, Director | Mar 24, 2026 | 62,000 | $459.42K | Mar 24, 2026 | Incentive Compensation Stock Grant |
| Giroux Richard Officer | Oct 21, 2025 | 24,000 | $212.88K | Oct 21, 2025 | Stock Bonus |
| Forbes Alexandria Officer, Director | Oct 7, 2025 | 47,500 | $398.53K | Oct 7, 2025 | Incentive Compensation Stock Grant |
| Giroux Richard Officer | Jul 22, 2025 | 24,000 | $204.48K | Jul 22, 2025 | Stock Bonus |
| Forbes Alexandria Officer, Director | Jul 8, 2025 | 47,500 | $378.58K | Jul 8, 2025 | Incentive Compensation Stock Grant |
| Giroux Richard Officer | Apr 22, 2025 | 24,000 | $144.00K | Apr 22, 2025 | Stock Bonus |
| Alexandria Forbes President / CEO | Apr 8, 2025 | 47,500 | $251.27K | Apr 8, 2025 | Stock Bonus |
| Richard Giroux Officer | Jan 21, 2025 | 24,000 | $153.84K | Jan 21, 2025 | Stock Bonus |